Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
152 BRL | +3,61% | +4,19% | +62,71% |
Vakgebied
- endocrinologie (57,7%): producten voor de behandeling van osteoporose, diabetes en groeiproblemen;
- oncologie (19,5%);
- immunologische ziekten (11,1%);
- neurologie (8,4%): voornamelijk geneesmiddelen voor de behandeling van depressie en schizofrenie;
- overige (3,3%).
De netto-omzet is als volgt geografisch verdeeld: Verenigde Staten (63,9%), Europa (18,1%), Japan (4,9%), China (4,5%) en overige (8,6%).
Aantal werknemers: 43 000
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80% |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62% |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30% |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28% |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01-01-96 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-23 |
Alonzo Weems
CMP | Compliance Officer | - | 01-01-97 |
Chief Tech/Sci/R&D Officer | 50 | 01-01-18 | |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17-05-21 |
Johna Norton
PRN | Corporate Officer/Principal | 57 | 01-04-17 |
Corporate Officer/Principal | - | 01-01-05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
- | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 63 | 25-01-21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01-04-09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01-01-05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01-02-16 |
William Kaelin
BRD | Director/Board Member | 66 | 04-06-12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01-01-96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01-10-16 |
Director/Board Member | 52 | 12-12-11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01-09-13 |
Karen Walker
BRD | Director/Board Member | 62 | 01-12-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 950 770 386 | 948 828 714 ( 99,80 %) | 365 000 ( 0,0384 %) | 99,80 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6.25% | 2 548 145 | 6.25% | 147 792 410 $ |
8 084 411 | 6.83% | 50 293 848 $ | |
PROQR THERAPEUTICS N.V. 16.55% | 13 371 562 | 16.55% | 26 208 262 $ |
4 000 000 | 9.40% | 20 920 000 $ | |
21 776 804 | 7.60% | 11 332 213 $ | |
AC IMMUNE SA 3.64% | 3 615 328 | 3.64% | 8 279 101 $ |
125 405 | 1.81% | 1 218 937 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Eli Lilly Export SA (Switzerland)
Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Kinsale Financial Services
| |
Lilly Nederland Finance BV
Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The company is based in Utrecht, Netherlands. |
Miscellaneous Commercial Services
|
Eli Lilly SA
Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Eli Lilly (Suisse) SA
| |
Lilly Global Nederland Holdings BV
Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The company is based in Utrecht, Netherlands. |
Financial Conglomerates
|
Eli Lilly Vostok SA
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,95% | 632 mld. | |
-6,16% | 354 mld. | |
+19,86% | 331 mld. | |
+9,32% | 299 mld. | |
+18,45% | 248 mld. | |
+11,88% | 216 mld. | |
-0,78% | 219 mld. | |
+5,90% | 164 mld. | |
-0,73% | 162 mld. |
- Beurs
- Aandelen
- Koers LLY
- Koers LILY34
- Onderneming Eli Lilly and Company